Dose-response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer.

Dose-response curves (DRCs) and the quantitative parameters describing these curves were generated for grade 3 oral mucositis and dysphagia in 144 patients using individual patient DVHs. Curve fits to the oral mucositis clinical data yielded parameter values of mean dose in 2 Gy equivalent, MD(50) = 51 Gy (95% CI 40-61), slope of the curve, k = 1(95% CI 0.6-1.5). R(2) value for the goodness of fit was 0.80. Fits to the grade 3 dysphagia clinical data yielded parameter values of MD(50) = 44.5 Gy (95% CI 36-53), k = 2.6 (95% CI 0.8-4.5). R(2) value for the goodness of fit was 0.65. This is the first study to derive DRCs in patients receiving induction chemotherapy followed by chemo-radiation (IC-C-IMRT) for head and neck cancer. The dose-response model described in this study could be useful for comparing acute mucositis rates for different dose-fractionation schedules when using IMRT for head and neck cancer.

[1]  A. Paccagnella,et al.  Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. , 2004, Journal of the National Cancer Institute.

[2]  Holly Ning,et al.  Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  S. Bentzen.  Dose–response relationships in radiotherapy , 2009 .

[4]  D. Donath,et al.  Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach. , 2011, International Journal of Radiation Oncology, Biology, Physics.

[5]  G J Kutcher,et al.  Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. , 1995, International journal of radiation oncology, biology, physics.

[6]  S. Bhide,et al.  Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. , 2012, International journal of radiation oncology, biology, physics.

[7]  L. Weir,et al.  A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  J. Lefebvre.  Laryngeal preservation in head and neck cancer: multidisciplinary approach. , 2006, The Lancet. Oncology.

[9]  N. Nelson,et al.  Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Slevin,et al.  Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: a retrospective review. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  B. Coche-Déquéant,et al.  Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma , 2000, British Journal of Cancer.

[12]  J. Bourhis,et al.  End points for new agents in induction chemotherapy for locally advanced head and neck cancers. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Masumi Kadoya,et al.  Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  S. Dische,et al.  Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Joseph O Deasy,et al.  The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. , 2010, International journal of radiation oncology, biology, physics.

[16]  M. Poulsen,et al.  Mucosal regeneration during radiotherapy , 1996 .

[17]  J. Fowler.  Apparent rates of proliferation of acutely responding normal tissues during radiotherapy of head and neck cancer. , 1991, International journal of radiation oncology, biology, physics.

[18]  L. Collette,et al.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. , 1996, Journal of the National Cancer Institute.

[19]  G. Sanguineti,et al.  Weekly dose-volume parameters of mucosa and constrictor muscles predict the use of percutaneous endoscopic gastrostomy during exclusive intensity-modulated radiotherapy for oropharyngeal cancer. , 2011, International journal of radiation oncology, biology, physics.

[20]  D. Dearnaley,et al.  A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  J. Kaanders,et al.  Accelerated fractionation radiotherapy for laryngeal cancer, acute, and late toxicity. , 1992, International journal of radiation oncology, biology, physics.

[22]  L. Dawson,et al.  Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.

[23]  J. Langendijk,et al.  The potential benefit of swallowing sparing intensity modulated radiotherapy to reduce swallowing dysfunction: an in silico planning comparative study. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  J. Bourhis,et al.  Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  Michael C. Joiner,et al.  Basic Clinical Radiobiology , 2009 .

[26]  J. Purdy,et al.  Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. , 2010, International journal of radiation oncology, biology, physics.

[27]  Avraham Eisbruch,et al.  Radiation dose-volume effects in the larynx and pharynx. , 2010, International journal of radiation oncology, biology, physics.

[28]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  J. Fowler,et al.  Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[31]  J. Pignon,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta analysis of chemotherapy on head and neck cancer , 2001 .

[32]  D. Ronis,et al.  Variables associated with feeding tube placement in head and neck cancer. , 2006, Archives of otolaryngology--head & neck surgery.

[33]  S. Bhide,et al.  Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer , 2008, British Journal of Cancer.

[34]  W. Dörr,et al.  Radiation-induced changes in cellularity and proliferation in human oral mucosa. , 2002, International journal of radiation oncology, biology, physics.

[35]  K. Harrington,et al.  Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[36]  H D Thames,et al.  Time-dose factors in radiotherapy: a review of the human data. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  S. Bentzen.  Radiobiological considerations in the design of clinical trials. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[38]  Lawrence B Marks,et al.  Normal tissue effects: reporting and analysis. , 2003, Seminars in radiation oncology.

[39]  L J Peters,et al.  A new isoeffect curve for change in dose per fraction. , 1983, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  B. Maciejewski,et al.  Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  D. Rietveld,et al.  A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  C. Gwede,et al.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.